2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 966

In Search of Mechanisms Underlying Fibroblast-like Synoviocyte Cell-to-Cell Cargo Transfer
Abstract Number: 955

In Vitro Effects of CR6086, a Potent ProstaglandinE2 Subtype 4 Receptor Antagonist, on Bone Erosive Pathways
Abstract Number: 52

In Vivo Effect of Opticin Deficiency in a Surgically Induced Mouse Model of Osteoarthritis
Abstract Number: 1573

In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis
Abstract Number: 1387

In-Depth Temperature of Small and Large Joints Assessed By Microwave Radiometry As an Additional Biomarker in Rheumatoid Arthritis
Abstract Number: 2411

In-Hospital Risk of Asthma in Patients with Rheumatoid Arthritis: A Cross-Sectional Nationwide Analysis
Abstract Number: 1478

Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 997

Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Abstract Number: 1625

Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 2384

Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 1777

Incidence and Prevalence of Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Health Management Organization: A 15-Year Study
Abstract Number: 723

Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up
Abstract Number: 815

Incidence in Large Vessel GCA in Northern Italy during a 11-Year Period
Abstract Number: 1483

Incidence of Cancer in a Cohort of Patients with Primary Sjögren Syndrome
Abstract Number: 2459

Incidence of Disease Worsening in Inflammatory Arthritis Patients on Long-Term Infliximab (Remicade®) Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].